The internal Scientific Meeting of IMI-PainCare took place in Netanya (Israel) and was hosted by the EFPIA partner TEVA Pharmaceuticals.

The meeting was a full success and the long-awaited first F2F meeting after more than two years! 45 attendees enjoyed this beautiful 2-days conference on-site and additional 62 members participated online via Zoom. The three subprojects PROMPT, BioPain and TRiPP reported their amazing progress and exciting results of preclinical, translational and clinical studies. Sufficient time was also given to foster cross-fertilization between the subprojects. A lot of new innovative science approaches in preclinical models, biomarkers and patient reported outcome measures (PROMs) in pain were discussed and further developed.  A highlight of the meeting was the talk by Jane Meijlink, who represented the partner patient organization International Painful Bladder Foundation. Jane gave an excellent overview of the classification of Interstitial Cystitis / Bladder Pain Syndrome.
What a great event, that brought us all together and stimulated scientific exchange within the consortium!
More information is planned to be presented in the December issue of the EFIC newsletter.